Who owns STML - STEMLINE THERAPEUTICS INC - COM based on 13F filings?

Open this security page to review the newest available 13F ownership history, top reported holders, and period-by-period changes.

STEMLINE THERAPEUTICS INC - COM (STML) Institutional Ownership

Q: What is CUSIP 85858C107?

CUSIP 85858C107 is the security identifier used in SEC filing datasets for STML - STEMLINE THERAPEUTICS INC - COM.

CUSIP: 85858C107

13F Institutional Holders and Ownership History from Q1 2014 to Q2 2020

Type / Class: Equity / COM
Symbol: STML

Reported Shares, Excluding Options vs Price

Reported Value, Excluding Options

Total Investors

Investment Quick Answers

What is CUSIP 85858C107?
CUSIP 85858C107 identifies STML - STEMLINE THERAPEUTICS INC - COM in SEC 13F datasets.

Where can I see the latest institutional holders?
Use the ownership history tables below to review the newest available institutional filing periods.

Continue Investment Research

Latest 13F filings for new institutional portfolio disclosures.
Latest Schedule 13D/13G reports for activist and beneficial ownership updates.
Latest 10-Q/10-K reports to cross-check issuer fundamentals.
Recent insider transactions for management buying/selling context.
SEC investors directory and top value investors for manager-level discovery.
All institutional ownership pages to compare adjacent CUSIP pages.

Recent Quarterly Holder Reports

Open recent reporting periods for CUSIP 85858C107:

Q2 2020 (0 holders) Q1 2020 (91 holders) Q4 2019 (96 holders) Q3 2019 (100 holders) Q2 2019 (96 holders) Q1 2019 (95 holders) Q4 2018 (90 holders) Q3 2018 (88 holders) Q2 2018 (91 holders) Q1 2018 (81 holders)

Institutional Holders of STEMLINE THERAPEUTICS INC - COM (STML) across Reporting Periods

Period	Reported Shares, Excl. Options	Value, Excl. Options	Value Change	Puts Notional Value	Calls Notional Value	Price (Median)	Investors
2020 Q2	0	$0	-$192,034,873	$0	$0		0
2020 Q1	39,703,174	$192,162,180	-$32,803,937	$133,000	$49,000	$4.84	91
2019 Q4	42,219,333	$448,791,180	-$5,297,320	$288,000	$130,000	$10.63	96
2019 Q3	42,603,906	$445,105,940	+$63,443,454	$758,000	$273,000	$10.41	100
2019 Q2	36,240,004	$555,137,228	+$43,143,778	$1,969,000	$683,000	$15.32	96
2019 Q1	33,910,727	$435,600,812	+$174,441,751	$1,929,000	$339,000	$12.85	95
2018 Q4	20,025,196	$190,256,243	+$490,883	$2,121,000	$1,425,000	$9.50	90
2018 Q3	19,860,266	$329,675,718	-$7,090,437	$3,564,000	$236,000	$16.60	88
2018 Q2	20,808,971	$333,938,885	+$9,407,318	$2,937,000	$250,000	$16.05	91
2018 Q1	20,263,333	$309,998,044	+$79,710,466	$2,110,000	$283,000	$15.30	81
2017 Q4	15,059,022	$234,920,276	+$42,033,622	$1,368,000	$2,037,000	$15.60	79
2017 Q3	12,881,851	$142,990,719	+$3,118,281	$1,695,000	$318,000	$11.10	76
2017 Q2	12,610,577	$116,017,342	-$9,853,957	$150,000	$618,000	$9.20	69
2017 Q1	13,902,927	$118,853,731	+$42,454,807	$501,000	$540,000	$8.55	73
2016 Q4	9,728,153	$104,090,173	+$8,340,985	$344,000	$309,000	$10.70	72
2016 Q3	8,951,002	$96,922,022	-$7,194,836	$171,000	$12,000	$10.83	68
2016 Q2	10,017,206	$67,810,933	-$922,678	$0	$4,000	$6.77	57
2016 Q1	10,181,923	$47,438,000	+$548,481	$57,000		$4.66	61
2015 Q4	10,046,854	$63,404,617	-$11,133,024	$0		$6.31	65
2015 Q3	10,921,689	$96,441,055	-$2,217,155	$398,000		$8.83	61
2015 Q2	11,123,545	$130,924,079	-$7,276,271			$11.77	71
2015 Q1	11,506,720	$166,495,178	+$55,432,275			$14.47	69
2014 Q4	7,637,375	$130,202,924	+$8,739,151	$0		$17.06	61
2014 Q3	7,155,617	$89,150,801	-$11,170,804	$199,000		$12.46	58
2014 Q2	7,920,666	$116,193,861	-$10,041,046			$14.67	58
2014 Q1	8,438,660	$171,786,274	+$2,800,896			$20.36	57